London Stock Exchange just joined this crypto

Today is the last session to position before Americans vote. The result traders are braced for is a Democratic sweep, and much of it is already reflected in prices. The more useful question entering the close is not whether Democrats win. Prediction markets have been pricing a Democratic sweep of Congress around the low-70% range, and Kalshi has had Democrats in the low-to-mid 90s to take the House. The question is which parts of that outcome are still open trades and which are done.

The dollar is the clearest signal. The U.S. dollar index finished Monday around 101.76 as traders froze positions ahead of Tuesday’s midterms. Currency traders rarely pay for certainty they already have. A House flip is the base case in most polling, so the dollar has little reason to move on that outcome alone. The rangebound action, with DXY pinned in a narrow 101 to 102 area through much of October, confirms the House result is largely absorbed. The Senate is where residual uncertainty lives.

What a Democratic Sweep Actually Moves

Healthcare has run hardest into the vote. Healthcare stocks have been quietly outperforming the broader market, with the S&P 500’s health care sector up a bit more than 9% over the last three months. The thesis centers on the Medicaid cuts baked into last year’s One Big Beautiful Bill Act. Democratic control of both chambers would raise the odds of delaying or moderating those cuts, particularly where reimbursement pressures hit hospital and provider economics. That rally already prices a House flip. A confirmed Senate sweep would be the incremental catalyst.

The critical distinction for healthcare names: a more supportive insurance environment could benefit providers, while tighter pricing rules could weigh on parts of the pharmaceutical and healthcare services industries. Hospital operators like HCA are positioned differently from large-cap pharma names. If Democrats capture only the House, it is difficult to see meaningful healthcare reform advancing, and even a full sweep could make delivery difficult. Eli Lilly sits at the complicated intersection: drug-pricing scrutiny is a Democratic priority, but drug stocks have still rallied into the election even though Democrats are often seen as more willing to curb pricing power.

On the other side of the ledger, some desks have framed election trades around regulatory targets, with variants of: long healthcare, renewables, and homebuilders, and short exposures more vulnerable to tougher oversight. Defense contractors have already absorbed some of the pain, with the group lagging amid worries that a Democratic sweep could bring tighter oversight and funding delays. Still, Wall Street has repeatedly noted that national-security spending often retains bipartisan support, particularly when geopolitical tensions are elevated. That limits the downside on names with genuine security mandates.

The bipartisan floor under defense spending has a structural reason behind it. The Pentagon’s public acknowledgment of on-orbit space weapons signals that counterspace procurement is moving toward open appropriations, a budget line that survives most political configurations.

A Democratic Congress could restore some support to solar and wind power, though the renewable trade has been punished this year regardless. A Senate win would reopen that thesis more than a House win alone.

The Risk Nobody Is Pricing: The Count Itself

A delayed result following the November 3 vote could surprise markets already on edge over rising government borrowing costs and AI jitters, as Man Group has warned in recent commentary about election-event volatility. It has also cautioned that options markets tend to price a bigger-than-usual move for the first session after Election Day, but still smaller than what gets priced around a presidential election, and that a delayed result can be the scenario that breaks positions built for a clean one.

That tail risk connects directly to the fiscal calendar. Congress will return after the midterms facing a compressed agenda, with government funding and several major authorizations converging around the December 11, 2026, deadline under the current continuing resolution. The continuing resolution does not resolve the FY 2027 appropriations process. Congress will need to continue negotiations on all 12 annual appropriations bills before that deadline. A contested count going into a lame-duck session already short on legislative days is a scenario for Treasury yield volatility, not calm.

Trader’s Action Plan

Hospital operators carry the highest-conviction Democratic sweep trade, but much of the easy move is behind us. The cleaner opportunity is in the Senate uncertainty premium: names most sensitive to a full sweep versus a split outcome have not yet fully resolved that gap. Watch the first Senate calls after 23:00 UK time tonight.

Size risk accordingly. Strategists caution investors not to tailor portfolios entirely to the election outcome, and a Democratic sweep would not guarantee lower bond yields, since inflation, energy prices, and fiscal confrontations could outweigh any reassurance. Carry modest position sizes through the count, keep dry powder for the December 11 fiscal deadline, and treat any multi-day delay in Senate calls as an opportunity to reduce exposure rather than add it.